Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
This article was originally published in The Pink Sheet Daily
The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.
You may also be interested in...
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.
Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.